NCT00629642 (SONIC) is a Phase 4 clinical trial of Solifenacin Succinate in Multiple Sclerosis, sponsored by Astellas Pharma Inc.

Who is sponsoring NCT00629642?

NCT00629642 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT00629642?

Interventions in NCT00629642: Solifenacin Succinate, Solifenacin Succinate, Oxybutynin Hydrochloride, Placebo.

What condition does NCT00629642 study?

NCT00629642 studies Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases.

Is NCT00629642 still recruiting?

NCT00629642 is currently completed. Last updated 14 November 2024.

Last reviewed 2024-11-14 · How we verify

NCT00629642: SONIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

Completed Phase 4 Last updated 14 November 2024

What this trial tests

Phase 4 trial testing Solifenacin Succinate in Multiple Sclerosis in 249 participants. Completed in 28 January 2011.

Timeline

14 March 2008

Primary endpoint
28 January 2011

28 January 2011

Quick facts

Lead sponsor	Astellas Pharma Inc
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	249
Start date	14 March 2008
Primary completion	28 January 2011
Estimated completion	28 January 2011
Sites	39 locations across France, Italy, Netherlands, Russia, Belgium, United Kingdom, Germany, Hungary

Drugs / interventions tested

Solifenacin Succinate — full drug profile →
Solifenacin Succinate — full drug profile →
Oxybutynin Hydrochloride
Placebo

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Neurogenic Bladder — all drugs for Neurogenic Bladder →
Spinal Cord Diseases — all drugs for Spinal Cord Diseases →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis or Neurogenic Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cells.
Lariosa-Willingham KD, Rosler ES, Tung JS, Dugas JC, et al · · 2016 · cited 52× · PMID 27592856 · DOI 10.1186/s13104-016-2220-2
Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions.
Lariosa-Willingham KD, Rosler ES, Tung JS, Dugas JC, et al · · 2016 · cited 6× · PMID 27629829 · DOI 10.1186/s13104-016-2219-8

Verify or expand the search:

Other trials of Solifenacin Succinate

Trials testing the same drug.

NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
NCT01747577 — Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After · Phase 4 · completed

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00629642 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 14 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00629642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing